The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
The U.S. FDA gave Nabriva Therapeutics a thumbs-up for the company’s oral and intravenous formulations of Xenleta (lefamulin) to treat community-acquired bacterial pneumonia in adults.
A new medical device for treating scoliosis – curvature of the spine – received FDA approval, providing an alternative that both corrects the curve and maintains flexibility in the spine.
Harmony Biosciences snagged approval from the U.S. FDA for the company’s first commercial product, a treatment for narcolepsy.
The U.S. Food and Drug Administration approved TB Alliance’s treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL.
Kala Pharmaceuticals Inc. received a complete response letter from the U.S. Food and Drug Administration regarding the company’s new drug application for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
Israel’s Nobio Ltd. received approval from the U.S. Food and Drug Administration to market an anti-bacterial composite designed to remain in the teeth for decades.
The U.S. Food and Drug Administration approved Daiichi Sankyo Co. Ltd.’s Turalio for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.
Finland’s Orion and Germany’s Bayer said on Wednesday the U.S. Food and Drug Administration had approved the prostate cancer drug Nubeqa (daroluramide), which the two companies have been developing together.
The U.S. Food and Drug Administration approved the anti-PD-1 therapy Keytruda as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.
The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!
